We are celebrating the successful listing of CPC Scientific’s parent company, MEDTIDE INC., on the Hong Kong Stock Exchange!
June 30, 2025
(June 30, 2025 – Hong Kong) – MEDTIDE INC. (the “Company”; Stock code: 03880) announced today that its shares have officially commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 03880. The successful listing marks a significant milestone in the Company’s global pharmaceutical development journey.
The listing is not the end point, but a new beginning. Looking ahead, we will:
- Strengthen our position as a global CRDMO specializing in peptides, enhancing the stability and reliability of our peptide-focused CRDMO services;
- Further develop our R&D capabilities and advance our technologies to maintain our competitive edge;
- Expand our global sales network to broaden our customer base;
- Strategically grow our oligonucleotide CDMO business and diversify our service offerings;
- Continue to attract, retain, and develop top talent.
This listing provides a valuable opportunity for MEDTIDE INC. to leverage global capital, accelerate business growth, and deliver strong performance while creating long-term value for shareholders, contributing to society, and benefiting the broader public.
About MEDTIDE INC.
MEDTIDE INC. is a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides. The Company provides end-to-end services from early discovery and preclinical research to clinical development and commercial manufacturing. Headquartered in Hangzhou, China, the Company operates commercial manufacturing sites and offices in both China and the United States.
With over 20 years of experience in the peptide field, MEDTIDE INC. is a globally integrated CRDMO with comprehensive service capabilities. Our CRDMO services cover the full pharmaceutical development lifecycle, including:
- CRO services – Discovery and synthesis of novel peptide chemical entities (NCEs);
- CDMO services – Peptide Chemistry, Manufacturing, and Controls (CMC) development and commercial production.
To date, we have served over 1,000 clients across more than 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea, and Australia, providing peptide drug synthesis, development, production, and regulatory CMC support in compliance with global standards.
As a trusted and steadily growing partner, MEDTIDE INC. has established long-term collaborations with many clients. Through close partnerships, we help bring life-changing therapies to market—always placing patients at the center and advancing global human health.
Learn more about MEDTIDE INC: https://www.medtideinc.com/